Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -569,183 | -606,639 | -707,421 | -454,025 | -186,566 |
| Depreciation Amortization | 22,919 | 13,164 | 20,919 | 19,845 | 13,109 |
| Income taxes - deferred | N/A | -1,619 | -1,639 | N/A | N/A |
| Accounts receivable | -33,598 | -22,778 | -12,068 | -5,432 | 9,840 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 32,313 | 26,853 |
| Other Working Capital | 13,918 | -13,482 | 61,874 | -63,236 | 104,663 |
| Other Operating Activity | 151,756 | 156,548 | 257,870 | 131,840 | -100,119 |
| Operating Cash Flow | $-414,188 | $-474,806 | $-380,465 | $-338,695 | $-132,220 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 4,659 | 219,815 | -79,754 | -201,180 | -172,441 |
| PPE Investments | -7,491 | -44,267 | -116,123 | -73,093 | -43,905 |
| Net Acquisitions | N/A | N/A | -75,025 | N/A | N/A |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -37,062 |
| Sale Of Investment | N/A | N/A | 10,094 | 79,843 | 79,842 |
| Purchase Sale Intangibles | -12,500 | -2,500 | -30,000 | N/A | N/A |
| Other Investing Activity | -14,936 | -7,548 | -30,844 | -942 | -5,555 |
| Investing Cash Flow | $-17,768 | $168,000 | $-291,652 | $-195,372 | $-179,121 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 399,241 | 388,170 | 10,813 | 119,044 | 600,508 |
| Other Financing Activity | 0 | -28 | 490,395 | -492 | -236 |
| Financing Cash Flow | $399,241 | $388,142 | $501,208 | $118,552 | $600,272 |
| Exchange Rate Effect | -2,525 | 462 | -1,075 | -1,194 | 1,119 |
| Beginning Cash Position | 219,399 | 137,601 | 309,585 | 726,294 | 436,244 |
| End Cash Position | 184,159 | 219,399 | 137,601 | 309,585 | 726,294 |
| Net Cash Flow | $-35,240 | $81,798 | $-171,984 | $-416,709 | $290,050 |
| Free Cash Flow | |||||
| Operating Cash Flow | -414,188 | -474,806 | -380,465 | -338,695 | -132,220 |
| Capital Expenditure | -7,491 | -44,267 | -116,123 | -73,093 | -43,905 |
| Free Cash Flow | -421,679 | -519,073 | -496,588 | -411,788 | -176,125 |